Abstract

Nephrotic syndrome (NS) predisposes to venous thromboembolic events with membranous nephropathy carrying the highest risk.1 Clinicians caring for patients with NS must balance the benefits of anticoagulation against potential harms, primarily bleeding. The management of venous thromboembolic events risk is complicated by little quality data examining anticoagulation for thromboprophylaxis in NS. A well-conducted, randomized controlled trial could inform which patients might benefit most from anticoagulation and the optimal agents.